Literature DB >> 32800803

Radiation Therapy and the In Situ Vaccination Approach.

Encouse B Golden1, Ariel E Marciscano1, Silvia C Formenti2.   

Abstract

During the past century, from the advent of preclinical modeling to the establishment of clinical trials, the hypothesis that host defenses regulate tumor growth (posited and refined by leaders in the field of cancer immunity) has become accepted as a scientific pillar in oncology. Since the turn of the millennium, a search has been under way for the best therapeutic approach to reprogram the immune system to recognize tumor cells that have undergone "immune escape." This quest has led some to question conventional scientific views of tumor cell kill, including the role of host immunity in patients treated with radiation therapy. In the last two decades, evidence has accumulated that radiation therapy can effectively convert a potentially lethal cancer into an in situ personalized vaccine. Herein, we review the underlying mechanisms and maneuvers responsible for in situ vaccine production.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32800803     DOI: 10.1016/j.ijrobp.2020.08.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.

Authors:  Rodney Cheng-En Hsieh; Sunil Krishnan; Ren-Chin Wu; Akash R Boda; Arthur Liu; Michelle Winkler; Wen-Hao Hsu; Steven Hsesheng Lin; Mien-Chie Hung; Li-Chuan Chan; Krithikaa Rajkumar Bhanu; Anupallavi Srinivasamani; Ricardo Alexandre De Azevedo; Yung-Chih Chou; Ronald A DePinho; Matthew Gubin; Eduardo Vilar; Chao Hsien Chen; Ravaen Slay; Priyamvada Jayaprakash; Shweta Mahendra Hegde; Genevieve Hartley; Spencer T Lea; Rishika Prasad; Brittany Morrow; Coline Agnes Couillault; Madeline Steiner; Chun-Chieh Wang; Bhanu Prasad Venkatesulu; Cullen Taniguchi; Yon Son Betty Kim; Junjie Chen; Nils-Petter Rudqvist; Michael A Curran
Journal:  Sci Immunol       Date:  2022-06-10

2.  Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer.

Authors:  Giulia Petroni; Aitziber Buqué; Takahiro Yamazaki; Norma Bloy; Maurizio Di Liberto; Selina Chen-Kiang; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Clin Cancer Res       Date:  2021-01-25       Impact factor: 12.531

Review 3.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

4.  Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy.

Authors:  Yu-Hung Lee; Ching-Fang Yu; Ying-Chieh Yang; Ji-Hong Hong; Chi-Shiun Chiang
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

Review 5.  Brain metastases: increasingly precision medicine-a narrative review.

Authors:  Michael Jerome McKay
Journal:  Ann Transl Med       Date:  2021-11

6.  PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation.

Authors:  Yi Na Yoon; Eunju Lee; Young-Ju Kwon; Jeong-An Gim; Tae-Jin Kim; Jae-Sung Kim
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 7.  Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.

Authors:  Fernando Torres Andón; Sergio Leon; Aldo Ummarino; Esther Redin; Paola Allavena; Diego Serrano; Clément Anfray; Alfonso Calvo
Journal:  Biomedicines       Date:  2022-07-04

8.  PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.

Authors:  Yuehong Kong; Xiangrong Zhao; Meiling Xu; Jie Pan; Yifu Ma; Li Zou; Qiliang Peng; Junjun Zhang; Cunjin Su; Zhi Xu; Wei Zhou; Yong Peng; Jiabao Yang; Chengliang Zhou; Yujia Li; Qiuchen Guo; Guangqiang Chen; Hongya Wu; Pengfei Xing; Liyuan Zhang
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 9.  Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.

Authors:  Sergi Benavente; Almudena Sánchez-García; Silvia Naches; Matilde Esther LLeonart; Juan Lorente
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

10.  Three discipline collaborative radiation therapy (3DCRT) special debate: Peer review in radiation oncology is more effective today than 20 years ago.

Authors:  Anis Ahmad; Lakshmi Santanam; Abhishek A Solanki; Laura Padilla; Erina Vlashi; Patrizia Guerrieri; Michael M Dominello; Jay Burmeister; Michael C Joiner
Journal:  J Appl Clin Med Phys       Date:  2020-11-24       Impact factor: 2.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.